Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FDG-PET lymphoma demonstration project invitational workshop.

Gary J Kelloff1, Daniel M Sullivan, Wyndham Wilson

  • 1National Institutes of Health (NIH)/National Cancer Institute (NCI)/Division of Cancer Treatment and Diagnosis (DCTD)/Cancer Imaging Program, Bethesda, MD, USA.

Academic Radiology
|February 20, 2007
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Associations of gait speed, grip strength, depressive symptoms, and their combinations with fracture risk in older adults.

GeroScience·2026
Same author

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Kidney Involvement in Sarcoidosis-Lymphoma Syndrome: A Report of Two Cases.

CEN case reports·2026
Same author

Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I Study.

Cancers·2026
Same author

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Cancers·2026
Same journal

Homogeneity of Liver Fat Distribution Serves as a Diagnostic Marker for Metabolic Dysfunction-Associated Steatohepatitis.

Academic radiology·2026
Same journal

MRI-based Predictors and Risk Constellations of Chronic Ankle Instability After Acute Lateral Ankle Sprain: A Multicenter Study.

Academic radiology·2026
Same journal

Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer using a Longitudinal US-based Stack-model.

Academic radiology·2026
Same journal

Evaluating the Impact of Embolization on Outcomes in Iliopsoas Hematomas: A Multicenter Retrospective Propensity-matched Study.

Academic radiology·2026
Same journal

Comparison of Iterative Metal Artifact Reduction Presets In Ultra-high-resolution Photon-counting CT Angiography of Patients with Total Knee Endoprosthesis.

Academic radiology·2026
Same journal

Deep Learning for Opportunistic Vertebral Fracture Detection on Routine Thoraco-abdominal Computed Tomography: A Systematic Review and Hierarchical Summary Receiver Operating Characteristic Meta-analysis of Patient-level Diagnostic Test Accuracy.

Academic radiology·2026
See all related articles
This summary is machine-generated.

Fluorodeoxyglucose-positron emission tomography (FDG-PET) shows promise for measuring treatment response in non-Hodgkin lymphoma (NHL). Standardized FDG-PET criteria could accelerate clinical trials and drug approvals for lymphoma and other cancers.

Area of Science:

  • Oncology
  • Medical Imaging
  • Biomarker Development

Background:

  • Non-Hodgkin lymphoma (NHL) is a common cancer requiring effective treatment response assessment.
  • Current standards of care for NHL necessitate improved methods for evaluating therapeutic efficacy.
  • Fluorodeoxyglucose-positron emission tomography (FDG-PET) is an imaging technique with potential for cancer diagnosis and staging.

Purpose of the Study:

  • To evaluate FDG-PET as a tool for measuring treatment response in NHL.
  • To propose the development of a clinical trial to validate FDG-PET as a predictive biomarker for cancer therapy response.
  • To foster collaboration between regulatory agencies, academia, and industry for biomarker qualification.

Main Methods:

  • Workshop proceedings focused on FDG-PET evaluation for NHL treatment response.

Related Experiment Videos

  • Review of NHL etiology and current standards of care.
  • Proposal for a clinical trial to validate FDG-PET imaging techniques.

    • Main Results:

    • FDG-PET demonstrates potential for early indication of therapeutic response in NHL.
    • This response is correlated with clinical outcomes for chemotherapy.
    • Standardized FDG-PET criteria can streamline clinical trials for lymphoma and other cancers.

    Conclusions:

    • FDG-PET holds significant promise as a biomarker for assessing treatment response in NHL.
    • Standardization of FDG-PET imaging and data handling is crucial for its widespread adoption.
    • This initiative could accelerate the development and approval of new cancer therapies.